This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

The company is also studying Zepbound’s impact on illness and death in a trial that’s due to deliver results in 2027. Patients who are more obese may ultimately do better with Zepbound, said ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See why NVO stock is a buy.

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

It would behoove more Americans to learn how consistent seafood consumption has strong potential to ward off coronary disease ...

GLP-1 medications for weight loss are all the rage, but they come with some side effects. Here are my top 10 supplements I take everyday while on Zepbound.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $943.0, a high ...